# Stem cell transplant: conditioning, the low blood count phase and engraftment monitoring

Source: https://onco.cc/protocols/hct-conditioning-and-engraftment-care/  
OnCo record `hct-conditioning-and-engraftment-care` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Before a stem cell transplant you have conditioning: chemotherapy, sometimes with radiotherapy, usually over 1 to 10 days. It destroys unhealthy blood cells and holds back the immune system so the new cells can settle. For some weeks the blood counts are very low, so the team guards against infection, gives transfusions and checks the blood often until the new cells start working (engraftment).

## Summary

This protocol covers the weeks from the start of conditioning to documented engraftment; the reader's own unit's policy comes first. Before conditioning starts, the attending physician confirms that the donor or product is available and suitable, and the regimen is given from standardised orders checked by a pharmacist and verified at the bedside by two people or one person with a validated process (FACT-JACIE 9.1, B7.2 and B7.4, all 'shall' standards). Total body irradiation needs a prior radiation oncology consultation (B7.5.1). Regimen intensity (myeloablative, reduced toxicity, reduced intensity, non-myeloablative) is chosen by age, comorbidity, disease status and measurable residual disease (EBMT Handbook 2024). The 2009 working definitions call a regimen myeloablative when it causes irreversible or nearly irreversible pancytopenia and stem cell support is required (their examples: total body irradiation of 5 Gy or more in a single dose or 8 Gy or more fractionated, or busulfan above 8 mg/kg by mouth or the intravenous equivalent), non-myeloablative when it causes minimal cytopenia and needs no stem cell support (example: total body irradiation of 2 Gy or less with or without a purine analogue), and reduced intensity when it fits neither. High-dose busulfan needs anticonvulsant cover from 12 hours before the first dose to 24 hours after the last, and daily counts until engraftment (label). Two qualified people verify the patient, the product and the order before infusion (B7.6.5). During neutropenia: a single room if possible (2009 global guidelines BIII; a protective environment room with HEPA filtration 'ideally', AIII for the filter), hand hygiene (AII), irradiated cellular blood components (Handbook). On growth factor after transplant the sources differ: the 2009 guidelines make no recommendation (CI); the Handbook advises considering G-CSF where the risk of graft failure is high. Neutrophil recovery is the first of 3 successive days with a count of 500 per microlitre or more; platelet recovery the first of 3 consecutive days at 20,000 per microlitre or more in the absence of platelet transfusion for 7 consecutive days; primary graft failure is no neutrophil recovery by day +30 (blood or marrow grafts) or day +42 (cord blood), with pancytopenia, confirmed by chimerism (EBMT, ASTCT, CIBMTR and APBMT, 2024). Fever with rash or breathlessness around engraftment that is not infection may be engraftment syndrome; the Handbook's authors advise stopping G-CSF, taking cultures and starting broad-spectrum antibiotics, then after 48 hours methylprednisolone 1 mg/kg every 12 hours intravenously for 3 days, tapered over a week.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: haematopoietic cell transplant conditioning; HCT conditioning; HSCT conditioning; bone marrow transplant conditioning; preparative regimen; engraftment monitoring; neutrophil engraftment; platelet engraftment; graft failure; chimerism testing; engraftment syndrome; neutropenic phase after transplant

## Connected records

- protocols: [Aciclovir prophylaxis against herpes simplex and shingles during cancer treatment](https://onco.cc/protocols/herpes-simplex-and-zoster-antiviral-prophylaxis/), [Antibacterial (fluoroquinolone) prophylaxis during expected severe neutropenia](https://onco.cc/protocols/antibacterial-prophylaxis-in-neutropenia/), [Antifungal prophylaxis for people at high risk of invasive fungal infection](https://onco.cc/protocols/antifungal-prophylaxis-in-haematology/), [Food safety during cancer treatment and the evidence against neutropenic diets](https://onco.cc/protocols/food-safety-and-neutropenic-diet/), [GVHD prophylaxis after allogeneic stem cell transplant: choosing the regimen](https://onco.cc/protocols/allo-hct-gvhd-prophylaxis/), [Ifosfamide: bladder protection with mesna and fluids, and ifosfamide encephalopathy](https://onco.cc/protocols/ifosfamide-bladder-protection-and-encephalopathy/), [Liver toxicity and veno-occlusive disease on inotuzumab ozogamicin and gemtuzumab ozogamicin: risk reduction, monitoring, hold and stop rules](https://onco.cc/protocols/veno-occlusive-disease-on-inotuzumab-and-gemtuzumab-ozogamicin/), [Lymphodepleting chemotherapy before CAR T-cell infusion](https://onco.cc/protocols/car-t-lymphodepletion/), [Oral care and oral mucositis prevention during cancer treatment](https://onco.cc/protocols/oral-mucositis-prevention-and-oral-care/), [Peripheral blood stem cell mobilisation and collection for transplant, in patients and donors](https://onco.cc/protocols/stem-cell-mobilisation-and-collection/), [Pneumocystis pneumonia (PJP) prophylaxis with co-trimoxazole](https://onco.cc/protocols/pneumocystis-pneumonia-prophylaxis/), [Protective measures and daily life during neutropenia: hand hygiene, visitors, pets, plants, school and swimming](https://onco.cc/protocols/neutropenic-precautions-and-daily-life/), [Red cell and platelet transfusion thresholds in cancer care](https://onco.cc/protocols/red-cell-and-platelet-transfusion-thresholds/), [Suspected febrile neutropenia (neutropenic sepsis): the first hour](https://onco.cc/protocols/febrile-neutropenia-first-hour/), [Vaccination before, during and after cancer treatment](https://onco.cc/protocols/vaccination-around-cancer-treatment/), [Veno-occlusive disease of the liver (sinusoidal obstruction syndrome) after stem cell transplant: prevention, monitoring, diagnosis and defibrotide](https://onco.cc/protocols/hepatic-veno-occlusive-disease-after-transplant/)
- drugs: [Busulfan](https://onco.cc/drugs/busulfan/), [Filgrastim (G-CSF)](https://onco.cc/drugs/filgrastim/), [Fludarabine](https://onco.cc/drugs/fludarabine/), [Melphalan (including hepatic delivery system)](https://onco.cc/drugs/melphalan/), [Thiotepa](https://onco.cc/drugs/thiotepa/), [Treosulfan](https://onco.cc/drugs/treosulfan/)
- technologies: [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/), [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/), [Total body and total marrow irradiation](https://onco.cc/technologies/total-body-irradiation/)
- terms: [Conditioning regimen (myeloablative, reduced-intensity)](https://onco.cc/terms/conditioning-regimen/), [Graft-versus-host disease (GVHD) and graft-versus-leukaemia](https://onco.cc/terms/gvhd/), [Neutropenia](https://onco.cc/terms/neutropenia/)

---
JSON: https://onco.cc/api/v1/entities/hct-conditioning-and-engraftment-care.json